Sofgen Pharma S.A PROCF
0.00
0.00
NaN
as of 24 Sep
- Market cap
- $114.0M
- P/E
- 0.0×
Follow PROCF
| Older periods | Mar '23 | Jun '23 | Sep '23 | Dec '23 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(363.02%) | 4,898.25% | 327.75% | (213.06%) | |
| 5.69% | 12.52% | 9.44% | 8.82% | ||
ROIC |
2.47% | 1.57% | 0.71% | 15.21% | |
Return on Tangible Assets |
22.32% | 41.94% | 23.77% | (60.27%) | |
Average Days of Receivables |
105.72 | 124.79 | 128.17 | 107.54 | |
Free Cash Flow per Share |
(0.21) | (0.09) | 0.32 | 0.74 | |
Free Cash Flow |
(20.95) | (9.43) | 31.99 | 74.84 | |
Capital Expenditures |
(33.28) | (32.22) | (32.44) | (32.79) | |
Piotroski F-Score |
4.00 | 3.00 | 4.00 | 6.00 | |
| Other line items | |||||
Cash ROIC |
3.89% | 6.62% | 17.98% | 31.31% | |
Accounts Receivable Turnover |
3.53 | 3.11 | 2.99 | 3.66 | |
Accounts Payable Turnover |
2.23 | 2.00 | 1.99 | 0.00 | |
Inventory Turnover |
1.70 | 1.74 | 1.85 | 1.84 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Days of Inventory on Hand |
215.84 | 213.68 | 194.98 | 200.06 | |
Tax Rate |
(0.24) | (0.26) | (0.27) | (0.12) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
48.73% | 46.91% | 47.22% | 45.63% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.47 | 0.38 | 1.41 | 2.67 | |
Depreciation/Fixed assets |
0.21 | 0.18 | 0.18 | 0.20 | |
Capex/Depreciation |
(1.95) | (1.95) | (1.86) | (1.80) | |
Revenue per Share |
3.97 | 3.95 | 4.03 | 4.20 | |
Operating CF per Share |
0.12 | 0.23 | 0.64 | 1.07 | |
Capex per Share |
(0.33) | (0.32) | (0.32) | (0.32) | |
Capex to Sales |
0.08 | 0.08 | 0.08 | 0.08 | |
Net Profit Margin |
6.55% | 15.07% | 11.24% | 9.52% |
Columns are period end dates